Valo Therapeutics
Helsinki
About Valo Therapeutics
Valo Therapeutics is an immunotherapy company that is developing antigen-coated oncolytic viruses as anti-cancer therapeutic vaccines. The company utilizes novel methods such as antigen-coated oncolytic viruses and vaccine vectors in its cancer treatment strategies. The Valo Tx platform, PeptiCRAd (Peptide-coated Conditionally Replicating Adenovirus), was developed out of the laboratory of Professor Vincenzo Cerullo at the University of Helsinki. It turns oncolytic adenoviruses into targeted tissue-specific cancer vaccines without the need to generate and manufacture multiple genetically modified viruses. The company is also developing PeptiENV, among other neoantigen strategies, in collaboration with Professor Cerullo. PeptiENV is expected to improve the therapeutic response to enveloped oncolytic viruses in the treatment of multiple forms of cancer.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $32.2M
- Last round: Series Unknown (Mar 2025)
- Website: valotx.com
- Phone: +44 20 3920 7649
Industries & Categories
Biotechnology, Health Care, Medical, Oncology, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/valo-therapeutics-20149 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.